An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for pa...
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
About this item
Full title
Author / Creator
Publisher
London: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central
Subjects
More information
Scope and Contents
Contents
Background Cabazitaxel significantly improves clinical outcomes compared with a second androgen receptor-targeted agent (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an ARTA (abiraterone or enzalutamide), as demonstrated in the CARD trial (NCT02485691). We aimed to estimate hea...
Alternative Titles
Full title
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6d4b407f4b4b48b78c689dd2fe67da45
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6d4b407f4b4b48b78c689dd2fe67da45
Other Identifiers
ISSN
1472-6963
E-ISSN
1472-6963
DOI
10.1186/s12913-022-08274-x
